Amylin Pharmaceuticals, Inc.

Indiana University

Astrazeneca Pharmaceuticals LP

David R Hathaway

Keith Leonard March

Brian L Patton

Robert L Wilensky

Andrew A Young

Kathryn Susan Prickett

Alain D Baron

Thomas R Coolidge

Nigel Robert Arnold Beeley

Richard J Roman

Mahesh Mistry

Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.

Treatment of cardiac arrhythmias

The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1), exendin, and analogs and agonists thereof, to subjects suffering therefrom.

Methods and compositions for treating polycystic ovary syndrome

The present invention relates to methods of treating intermittent claudication comprising administering glucagon-like peptide-1 (GLP-1) molecules to subjects suffering therefrom.

Compositions and methods for treating peripheral vascular disease

Treatment of cardiac arrhythmias with GLP-1 receptor ligands

The invention provides a device having two components: a needle advancing apparatus slidable longitudinally along a catheter to advance needles into a tissue membrane, such as a blood vessel wall, around an opening in the membrane; and, a suture retrieval assembly insertable through the catheter beyond a distal side of the tissue membrane. The needle advancing apparatus advances suture through the tissue wall. The suture retrieval assembly grabs the suture on the distal side of the tissue membrane for extraction thereof through the opening in the tissue membrane. A method for suturing a membrane beneath the patient's skin is also disclosed.

Apparatus and method for positive closure of an internal tissue membrane opening

The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1) to subjects suffering therefrom.

A drug delivery catheter assembly, including an expandable, porous outer membrane that is insertable into a blood vessel and positioned adjacent a stenotic atherosclerotic lesion on the interior wall of the blood vessel. The membrane is expanded into contact with the lesion, either mechanically or hydraulically. After the membrane is expanded, a drug-containing liquid is caused to flow into the membrane and through the pores in the membrane into contact with the lesion.

Method and apparatus for intravascular drug delivery

A method and composition for delivering a drug to an affected intramural site for sustained release in conjunction with or following balloon catheter procedures, such as angioplasty. The drug, carried by microparticles of a physiologically-compatible, biodegradable polymer is injected under directed pressure into the wall of a body vessel in the region of the affected site.

Method for delivery of smooth muscle cell inhibitors

Restenosis following vascular recanalization is prevented by administering a photoactivatable psoralen and, in conjunction with recanalization, delivering ultraviolet radiation to the region of said recanalization.

Growing community of inventors

Lincoln, NE, United States of America

David R Hathaway